JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

105.35 4.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

98.93

Max

106.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.9B

15B

Ankstesnė atidarymo kaina

101.24

Ankstesnė uždarymo kaina

105.35

Naujienos nuotaikos

By Acuity

50%

50%

139 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-08 23:57; UTC

Rinkos pokalbiai

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026-02-08 23:47; UTC

Rinkos pokalbiai

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026-02-08 23:43; UTC

Rinkos pokalbiai

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026-02-08 23:26; UTC

Rinkos pokalbiai

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026-02-08 21:43; UTC

Rinkos pokalbiai

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026-02-08 21:16; UTC

Rinkos pokalbiai

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026-02-08 21:15; UTC

Rinkos pokalbiai

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-07 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-07 02:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Money, High Anxiety -- Barrons.com

2026-02-06 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-06 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-06 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026-02-06 21:22; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026-02-06 21:17; UTC

Uždarbis

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026-02-06 21:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-06 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026-02-06 21:13; UTC

Uždarbis

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026-02-06 21:13; UTC

Uždarbis

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026-02-06 21:04; UTC

Rinkos pokalbiai

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026-02-06 20:34; UTC

Uždarbis

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

26% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  26%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

139 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat